thought to be one of the initial steps of atherosclerosis, little is known regarding how VE-cadherin is disrupted during atherogenic development. This study focused on the role of calpain, an intracellular cysteine protease, in the proteolytic disorganization of VE-cadherin and subsequent progression of atherosclerosis.
V ascular endothelial cells (ECs) cover the luminal surface of blood vasculature in a wall-to-wall manner. This conformational aspect is known to act as a physical barrier against plasma constituents and immunocompetent cells, which is critically important to ensure vascular integrity. Dysfunction of the EC barrier during the early stage of atherosclerosis leads to leakage of low-density lipoprotein (LDL) and extravasation of monocytes into the vessel walls, thereby accelerating atherosclerosis. 1, 2 
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Three major types of intercellular junctions have been identified in ECs: tight junctions, gap junctions, and adher-ence junctions (AJs). 3 Tight junctions are present in up to 20% of the total number of junctional complexes in ECs, whereas AJs are found in Ϸ90% of them. 4 AJs are composed of VE-cadherin, which forms Ca 2ϩ -sensitive and homophilic associations between adjacent ECs. 5 Administration of anti-VE-cadherin neutralizing antibody to mice results in vascular hyperpermeability without modifying other types of interendothelial junctions 6 ; therefore, VE-cadherin-mediated AJs have an essential role in maintaining EC barrier functions. Bobryshev et al 7 previously demonstrated that downregulation of VE-cadherin expression within intimal neovessels in human atherosclerotic lesions is accompanied by increased entry of immunocompetent cells into the intimal areas of neovascularization. Foteinos et al 8 similarly described down-regulation of VE-cadherin and increased vascular permeability in aortic intima in apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mice. It is therefore considered that VE-cadherin dysfunction has a proatherogenic effect on vessels; however, the molecular mechanisms of how AJs are disorganized during development of atherosclerosis remain largely obscure.
It has recently been documented that the Ca 2ϩ -sensitive intracellular cysteine protease calpain is capable of inducing proteolysis and functional disruption of both the neuronal (N)-and epithelial (E)-cadherin subtypes. 9, 10 Two ubiquitous forms of calpain,and m-calpain, require micromolar and millimolar levels of Ca 2ϩ for half-maximal activation, respectively. 11 Ubiquitous calpain is composed of a heterodimer of the common regulatory subunit, Capn4, and the subtype-specific large subunits, Capn1 and Capn2, which serve asand m-calpain isozymes, respectively. Deficiency of the Capn1 gene in mice results in a reduction in platelet aggregation and clot retraction 11 ; in contrast, Capn2-deficient mice appear to be embryonically lethal. 12 Similarly, deficiency of the Capn4 gene leads to an embryonically lethal phenotype, which is accompanied by impaired cardiovascular development and abnormal EC appearance. 13 Our previous study proposed that m-calpain, but not -calpain, dominantly participates in shear stress-induced motility and barrier regulation in vascular ECs, 14, 15 indicating that m-calpain has a fundamental role in the cardiovascular system and/or EC functions. However, the roles of calpain in atherosclerosis and VE-cadherin processing have not yet been fully established. In this study, we addressed the question of whether calpain proteolytically and functionally modifies the integrity of endothelial AJs during the process of atherosclerosis. The results showed that m-calpain is induced in ECs on human and murine atherosclerotic lesions in aorta, which promotes proteolytic disorganization of VE-cadherin and subsequent proatherogenic hyperpermeability as a trigger of atherosclerosis development.
Methods
An expanded discussion of material and methods is available in the online-only Data Supplement.
Human Aorta
Atherosclerotic lesions in human aortic samples, which were collected from 8 autopsy cases (5 male and 3 female patients; age, 26 -72 years; the Table) , were graded essentially on the basis of American Heart Association criteria. 16 Protein expression of m-calpain in aortic segments was detected by conventional immunohistochemistry with anti-m-calpain antibody (Abcam, Cambridge, MA). The study was approved by the Ethics Committee of Showa University School of Medicine.
Mice
All procedures involving animals were performed according to protocols approved by the faculties. LDL receptor-deficient (ldlr Ϫ/Ϫ ) and apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice served as wild-type controls. Mice were fed chow (CRF-1; Oriental Yeast, Tokyo, Japan) or a high-cholesterol diet (HCD; CRF-1 supplemented with 1.4% cholesterol and 0.4% cholic acid; Oriental Yeast) for 1 to 24 weeks starting at 8 weeks of age. Plasma lipid profiles were determined by Oriental Yeast using standard enzymatic methods. Plasma lysophosphatidylcholine (LPC) levels were measured with an LPC assay kit (AZWELL, Osaka, Japan).
Administration of Drugs and Small Interfering RNAs
For administrating calpain inhibitors, control vehicle (3% dimethyl sulfoxide), N-Acetyl-L-leucyl-L-leucyl-L-methioninal (ALLM; 5 mg/kg), or calpeptin (5 mg/kg) was dissolved in isotonic saline and administrated intraperitoneally to HCD-fed mice for 12 weeks at an interval of 2 days. For in vivo small interfering RNAs (siRNA) transfection, ldlr Ϫ/Ϫ mice were briefly anesthetized with diethyl ether, followed by intravenous administration of siRNA against m-calpain (10 g per body) or nonsilencing control RNA (10 g per body) involving TransIT-QR Hydrodynamic delivery solution (Mirus Bio, Madison, WI), as previously described. 15 The mice were fed HCD from day 2 (2 days after siRNA administration) and were euthanized on day 9. The nucleotide sequences of siRNA are displayed in Table I in the online-only Data Supplement.
Immunohistochemistry and Atherosclerotic Lesion Quantification
For immunohistochemical analysis in mice, the isolated aortic tree and root were fixed in 4% paraformaldehyde in PBS; they were subsequently frozen, sectioned at 6-m thickness, and mounted on glass slides as required. Target molecules were detected by the use of immunofluorescence histochemistry or conventional immunohistochemistry. For quantifying atherosclerotic lesions, paraformaldehyde-fixed aortic trees and roots were stained with Oil Red O in 60% isopropanol for 30 minutes. Specimens were washed with 60% isopropanol and photographed for calculation of positive areas with ImageJ software. Atherosclerotic lesions were graded essentially on the basis of American Heart Association criteria. Very mild indicates that intimal thickening is rarely observed. Mild, moderate, and severe are characterized by foam cell-enriched fatty streaks, advanced atheroma that contains lipid core, and plaques with large calcification, respectively.
Table. Clinicopathological Information and m-Calpain Expression in Endothelial Cells in Human Aorta

Aortic Permeability
For measuring aortic permeability, FITC-labeled BSA was intravenously administrated to the mice before isolation of the vessels as described previously. 15 One hour after administration of FITC-BSA, the circulation system was perfused with 4% paraformaldehyde in PBS. The aortic tree was then excised, and en face distribution of leaked FITC-BSA was imaged by confocal microscopy (LSM510; Carl Zeiss, Thornwood, NY). Aortic specimens were weighed and homogenized in 200 L PBS, and the insoluble fraction was removed by centrifugation. Fluorescence intensity of the supernatant was monitored with a microplate reader (excitation, 485 nm; emission, 535 nm).
Real-Time Reverse-Transcriptase Polymerase Chain Reaction
Total RNA derived from the whole aorta or scalped aortic intimal cells was converted to cDNA that served as a template of polymerase chain reactions as previously described. 15 Primer sequences used are shown in Table II in the online-only Data Supplement.
Cell Culture and Lysophospholipid Stimulus
Human umbilical vein ECs (HUVECs), which were purchased from Cambrex (Walkersville, MD), were cultured as previously described. 14, 15 Confluent cells from 4 to 7 passages were used in the experiments. For lysophospholipid stimulus, the cells were incubated with endothelial growth medium-2 (Cambrex) containing LPC (1palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine), lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate), or sphingosine-1-phosphate at 37°C.
Immunoblotting, Immunoprecipitation, and Casein Zymography
Immunoblotting was performed as previously described. 14, 15 Primary antibodies used are listed in Table III in the online-only Data Supplement. Immunoprecipitation was conducted with Dynabeads protein G (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. For measuring calpain activity with casein zymography, HUVEC lysate was separated by electrophoresis with the use of 12% polyacrylamide gels containing 0.2% casein sodium. Subsequently, the gels were incubated with Ca 2ϩ -containing reaction buffer overnight at room temperature, followed by staining with Coomassie blue.
Preparation of Modified LDL
Human LDL (dϭ1.019 -1.063 g/mL) was prepared as described previously. 17 To prepare oxidized LDL, LDL (0.1 mg/mL) was incubated for 20 hours at 37°C with 5 mol/L CuSO 4 , followed by the addition of 1 mmol/L EDTA and cooling. To prepare enzymatically hydrolyzed LDL, isolated LDL (500 g/mL) was incubated with recombinant human secreted phospholipase A 2 isoforms (group V, sPLA 2 -V; group X, sPLA 2 -X) at 1 g/mL for 16 hours at 37°C as described previously. 18 HUVECs were then incubated with 5-fold diluted sPLA 2 reactants.
In Vitro siRNA
HUVECs were transfected withor m-calpain siRNA (40 nmol/L) or control RNA (40 nmol/L) involving the siPORT NeoFX Transfection Agent (Ambion, Austin, TX) as previously described. 14, 15 Cells were subjected to experiments 48 hours after transfection. The nucleotide sequences of the siRNA are shown in Table I in the online-only Data Supplement.
Measurement of EC Barrier Functions In Vitro
The permeability assay was performed as previously described by Patterson et al 19 with a slight modification. HUVECs were cultured on cell culture inserts (0.4-m pore; Millipore, Bedford, MA) coated with collagen type I. After 60 minutes of stimulation, Evans blue dye bound to BSA, which was prepared by supplementing Dulbecco modified Eagle medium containing 10% BSA with Evans blue dye at 1 mg/mL, was added to the upper chamber of the insert. Optical absorbance of the medium in the lower chamber was monitored at 595 nm using a microplate reader. The albumin flux (F) across the monolayer was determined from the following equation: FϭdA/dt, where A is optical absorbance in the lower chamber and t is time. For measuring transendothelial electric resistance, HUVECs were cultured on cell culture inserts (0.4-m pore; Millipore) coated with collagen type I. Transendothelial electric resistance measurement was conducted with the EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL).
DNA Constructs and Mutagenesis
The human VE-cadherin construct was digested at appropriate restriction sites and ligated in-frame into the N-terminus site of the pAcGFP1-N2 vector (Clontech, Palo Alto, CA). VE-cadherin deletion mutants were generated by using mutagenic primers and the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). Primer sequences used in the recombination study are given in Table IV in the online-only Data Supplement. HUVECs were transfected with the expression vectors by lipofection involving Lipofectamine LTX regent (Invitrogen) or electroporation with Nucleofector II (Lonza) and Amaxa HUVEC Nucleofector kit (Lonza). Cells were subjected to experiments 24 hours after transfection. For evaluating VE-cadherin resistance to calpain-induced proteolysis, immunoprecipitated VE-cadherin was incubated with recombinant human -calpain or rat m-calpain (Calbiochem, San Diego, CA) at room temperature.
Data Analysis
Results are expressed as the meanϮSEM. The Mann-Whitney U test was used to determine the statistical differences between the 2 groups. Multiple comparisons were conducted with non-repeatedmeasures 1-way or 2-way ANOVA followed by a posthoc Bonferroni or Dunnett test as appropriate. A value of PϽ0.05 was considered statistically significant.
Results
Subtype-Selective m-Calpain Induction in Aortic ECs Accelerates Atherosclerosis Progression
We first investigated m-calpain expression in the aortic segments derived from 8 patients with various grades of atherosclerotic lesions (the Table) . Immunohistochemistry showed that m-calpain expression was prominent in particular in ECs on advanced atheroma in aorta ( Figure 1A) , whereas relatively weak m-calpain expression was noted in other component cells in the lesion. In the atheroma-free aorta, m-calpain immunoreactivity observed in intimal ECs and other vascular wall cells in aorta was much weaker ( Figure 1B ) than that in ECs on advanced atheroma ( Figure 1A) .
We then confirmed systemic expression of the 2 ubiquitous calpain subtypes,and m-calpains, in the chow-or HCDfed ldlr Ϫ/Ϫ mice by real-time reverse-transcriptase polymerase chain reaction (Figure 2A ). Although the expression levels of -calpain were reduced in the spleen during 12 weeks of HCD feeding, those of m-calpain were significantly increased in the aorta and lung compared with those in chow feeding (PϽ0.05). Confocal immunohistochemistry showed that the density of m-calpain-positive ECs was clearly increased in aortic intima in HCD-fed ldlr Ϫ/Ϫ mice compared with chow-fed mice ( Figure 2B ). Intense staining was restricted to ECs in superficial intima in the initial fatty-streak lesions and in the advanced lesions ( Figure 2B ), but it was not restricted to the elastin-enriched medial regions or plaque interior. Similar EC-specific localization of m-calpain was observed in lung in HCD-fed ldlr Ϫ/Ϫ mice. Real-time reverse-transcriptase polymerase chain reaction analysis showed that there was a marked increase in the expression of intimal m-calpain, but not -calpain, during 6 weeks of HCD feeding ( Figure 2C ).
Oxidized LDL and sPLA 2 -modified LDL are known to trigger proatherogenic responses in various cell types, including ECs 18, 20, 21 ; therefore, the effects of these modified LDLs on the expression of calpains were tested in cultured ECs ( Figure 2D ). Accordingly, the expression of m-calpain, but not -calpain, was dramatically elevated by administration of sPLA 2 -V-or sPLA 2 -X-modified LDL compared with the enzyme-alone groups, which increased m-calpain expression only modestly, and with native LDL, which had no influence on the expression. Similarly, subtype-specific m-calpain induction was also observed in HUVECs stimulated with oxidized LDL. Our preliminary data showed that the antioxidants N-acetylcysteine or superoxide dismutase did not attenuate the oxidized LDL-induced m-calpain induction, probably indicating that the induction was not due mainly to oxidative stress (data not shown).
Because proatherogenic lysophospholipids are reportedly accumulated in modified LDLs, 18, 22, 23 we investigated whether lysophospholipids directly induce calpain expression in cultured ECs (Figure 2E ). Exposure of HUVECs to LPC resulted in an increase in expression levels of m-calpain protein above 1 mol/L without altering those of -calpain ( Figure 2E ), which was accompanied by selective m-calpain overactivation ( Figure 2F ). In contrast, lysophosphatidic acid and sphingosine-1-phosphate failed to induce m-calpain in ECs (Figure 2E ). In agreement with the effect of LPC to induce m-calpain, sPLA 2 -treated LDL and oxidized LDL accumulated Ϸ300 to 500 nmol LPC per 1 mg protein ( Figure  I in the online-only Data Supplement).
The therapeutic effects of long-term administration of calpain inhibitors on atherosclerosis were then evaluated. Administration of each calpain inhibitor, calpeptin or ALLM, to ldlr Ϫ/Ϫ mice led to suppression of HCD-induced atherosclerosis in the aortic tree and root ( Figure 3A, left) , whereas plasma levels of LPC and total, LDL, and high-density lipoprotein cholesterol were unaffected (Table V in the online-only Data Supplement). In addition, calpeptin displayed a similar therapeutic effect on atherosclerosis in HCD-fed apoE Ϫ/Ϫ mice ( Figure 3A, right) . Moreover, mRNA expression levels of the proinflammatory markers, including nuclear factor-B, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, tumor necrosis factor-␣, interleukin-1␤, and interleukin-6, as well as the macrophage marker CD68, in the aortas in ldlr Ϫ/Ϫ mice were significantly decreased by the inhibitors (Figure 3B ). Furthermore, infiltration of macrophages into the vascular wall in the hypercholesterolemic mice, as assessed by immunohistochemistry with MOMA-2 antibody, was significantly decreased by the inhibitor treatment ( Figure 3C ).
m-Calpain Mediates VE-Cadherin Cleavage and Proatherogenic Hyperpermeability
Immunoblotting with anti-VE-cadherin antibody (H-72) indicated that 2 major bands, 135 kDa (intact VE-cadherin) and its Ϸ90-kDa fragment, were found in the whole aortic lysate. Furthermore, the expression ratio of the Ϸ90to 135-kDa band was significantly elevated in HCD-fed ldlr Ϫ/Ϫ mice within 6 weeks of diet initiation compared with that in the chow-fed mice (PϽ0.05; Figure 4A ). VE-cadherin cleavage, which was observed in aorta in HCD-fed ldlr Ϫ/Ϫ or apoE Ϫ/Ϫ mice, was prevented by the administration of calpeptin or ALLM ( Figure 4B ). It is noteworthy that the calpain inhibi- tion resulted in a parallel reduction in proteolysis of ␣-spectrin, a well-known calpain substrate. 11 Immunohistochemistry showed that the VE-cadherin disorganization, which was observed in aortic ECs in the hypercholesterolemic mice after treatment with dimethyl sulfoxide controls, was restored by inhibition of calpain ( Figure 4C ).
The effects of in vivo siRNA transfection on VE-cadherin cleavage and initial atherosclerotic hyperpermeability were investigated. Hydrodynamic transfection of m-calpain siRNA selectively diminished the expression of aortic m-calpain protein by 65.1Ϯ0.1% (meanϮSEM; nϭ4) at day 2 (2 days after transfection) compared with mice that received control RNA ( Figure II in the online-only Data Supplement). Although this m-calpain silencing was weakened at day 9, m-calpain expression remained at a 40.1Ϯ0.1% lower level (meanϮSEM; nϭ8) at this time point ( Figure 5A) , indicating that the effect of siRNA was sustained at least for 9 days. Cleavage of aortic VE-cadherin and ␣-spectrin was markedly inhibited by siRNA silencing of m-calpain at day 9 ( Figure  5A ) without normalization of plasma lipid profiles ( Table V in the online-only Data Supplement). An in vivo permeability assay showed that ldlr Ϫ/Ϫ mice fed HCD for 7 days displayed leakage of FITC-BSA, particularly in the inferior aspect of the aortic arch, which was not observed in the chow-fed mice ( Figure 5B ). Although administration of control RNA did not influence proatherogenic hyperpermeability in the aorta, it was largely attenuated by m-calpain silencing. 
LPC-Induced m-Calpain Cleaves VE-Cadherin, Leading to EC Barrier Dysfunction
Exposure of HUVECs to LPC, but not to lysophosphatidic acid or sphingosine-1-phosphate, resulted in an increasing cleavage of VE-cadherin above 1 mol/L ( Figure 6A ). This cleavage, which was detected similarly in ionomycin-stimulated HUVECs, was temporally correlated with m-calpain induction ( Figure III in the online-only Data Supplement). The calpain inhibitor calpeptin, the intracellular Ca 2ϩ chelator BAPTA/AM, the phospholipase C inhibitor U73122, and the extracellular signal-related kinase (ERK) kinase inhibitor U0126 were all effective for cancellation of LPC-induced VE-cadherin cleavage ( Figure 6B) . Immunoprecipitation experiments showed that treatment of HUVECs with LPC resulted in dissociation of ␤-catenin from VE-cadherin, an effect that was clearly cancelled by administration of calpeptin ( Figure 6C) . We further conducted siRNA-based inhibition experiments in HUVECs ( Figure 6D ). LPC-induced induction of m-calpain was observed in the control and -calpain knockdown cells but not in the m-calpain knockdown cells. LPCinduced VE-cadherin cleavage was detected equally in the control and -calpain knockdown cells. However, m-calpain knockdown cells did not respond to the stimuli. Moreover, although LPC administration facilitated albumin permeability (a marker of EC barrier function) identically in control and -calpain knockdown cells, it failed to do so in m-calpain knockdown cells ( Figure 6E ). Furthermore, transfection with the full-length human m-calpain gene in HUVECs resulted in a promotion of VE-cadherin cleavage and disorganization of AJs ( Figure IV 
m-Calpain Directly Cleaves VE-Cadherin at Juxtamembrane Regions
In vitro enzymatic experiments showed that recombinant m-calpain, but not -calpain, potently cleaved immunoprecipitated VE-cadherin ( Figure 7A ). Antibody-based epitope mapping indicated that the calpain cleavage site might reside in amino acid residues 651 to 722, a juxtamembrane region ( Figure V in the online-only Data Supplement). To gain support of the epitope mapping, the expression vectors encoding deleted VE-cadherin constructs lacking 5 amino acid residues-671 through 675 (671⌬5), 681 through 685 (681⌬5), or 691 through 695 (691⌬5)-were constructed and then transiently transfected into HUVECs. The expression levels of tagged VE-cadherin in cells transfected with wildtype or either of the deletion mutants were similar to those of endogenous VE-cadherin ( Figure VI in the online-only Data Supplement). Enzymatic study showed that 2 VE-cadherin mutant proteins, 671⌬5 and 681⌬5, were proteolyzed by recombinant m-calpain in an identical fashion to wild-type VE-cadherin, whereas the 691⌬5 mutant exhibited resistance to m-calpain-induced proteolysis ( Figure 7B) .
Confocal microscopic analysis showed that transfection of HUVECs with wild-type or mutant VE-cadherin led to peripheral localization of the green fluorescent protein fusion protein under unstimulated conditions ( Figure 7C ). Treatment of cells transfected with wild-type or the 681⌬5 mutant with LPC led to breakdown of AJs, whereas AJs in the 691⌬5 mutant were not disorganized by LPC stimulus. Furthermore, LPC-induced decreases in transendothelial electric resistance, which reflects AJ disorganization, were observed both in wild-type and 681⌬5 mutant but not in 691⌬5 mutant. Finally, although LPC administration facilitated albumin permeability equivalently in wild-type or the 681⌬5 mutant, the 691⌬5 mutant did not respond to the stimuli ( Figure 7D ).
Discussion
Our findings showed that the subtype-selective induction of m-calpain detected in aortic ECs in hypercholesterolemic mice participates in proteolytic disorganization of VEcadherin ( Figure 7E ). This observation is reminiscent of atherosclerosis in humans because EC-specific induction of m-calpain also occurs in atherosclerotic lesions in human aorta ( Figure 1 and the Table) . Considering that downregulation of VE-cadherin reportedly promotes extravasation of immunocompetent cells 7 or macromolecules into the vascular wall, 6,8 m-calpain-induced disorganization of VE-cadherin in aortic ECs may accelerate the progression of atherosclerotic lesions.
The proatherogenic role of -calpain has been predicted. ATP-binding cassette transporter A1 (ABCA1) in macrophages and hepatocytes is reportedly inactivated by -calpain-induced proteolysis. 24 Hepatic ABCA1 degradation observed in cholesterol-fed rabbits is decreased by the antioxidative hypolipidemic agent probucol, which leads to increased high-density lipoprotein biogenesis and thereby ameliorates atherosclerosis. 25 This finding suggests the potential contribution of -calpain to ABCA1 degradation during atherogenesis. However, we believe that this is not the case in hypercholesterolemic mice because direct inhibition of calpain by pharmacological inhibitors or siRNA attenuated the progression of atherosclerotic lesion in the mice without normalization of plasma cholesterol and high-density lipoprotein levels ( Table V in the online-only Data Supplement). Although the role of m-calpain subtype in the atherogenic process has not been previously investigated, our present data indicated that m-calpain is preferentially induced in ECs on atheroma rather than other component cells in atherosclerotic lesions (eg, smooth muscle cells or foam cells; Figures 1 and  2) . Thus, it is likely that m-calpain in vascular ECs has a key role in atherogenesis.
The present in vitro data further suggest, for the first time, that VE-cadherin is directly proteolyzed by m-calpain at a juxtamembrane region (Figure 7 ). N-cadherin appears to be cleaved by calpain at 4 or more additional regions of the cytoplasmic domain, including juxtamembrane regions. 9 Similarly, E-cadherin is reportedly proteolyzed by calpain at its juxtamembrane region. 10 Therefore, the calpain-induced cleavage sites in VE-cadherin resemble those in other cadherin families. The cytoplasmic domain of VE-cadherin contains a C-terminal site for binding to either ␤-catenin or ␥-catenin (plakoglobin) and a juxtamembrane site for binding to p120-catenin. 26 In addition, ␤-catenin and ␥-catenin are associated with ␣-catenin, which provides physical linkage of the cadherin complex to actin cytoskeleton. Navarro et al 27 demonstrated that a mutant VE-cadherin lacking the C-terminal tail (AA702-784) results in dissociation of ␣and ␤-catenin from VE-cadherin and that Chinese hamster ovary cells expressing truncated VE-cadherin display robust macromolecule permeability compared with those expressing nontruncated VE-cadherin. This is consistent with the present results showing that m-calpain-induced VE-cadherin cleavage in the juxtamembrane domain (adjacent to AA690 -695 residues) leads to ␤-catenin/VE-cadherin dissociation and barrier dysfunction in ECs (Figures 6 and 7) .
We now show that LPC, which can reach a nearly equal amount of intact phosphatidylcholine (a major phospholipid component) in oxidized LDL, 22 triggers the expression and proteolytic conversion of m-calpain in ECs (Figures 2 and 6 ). LPC reportedly decreases nitric oxide production and increases adhesion molecule expression in ECs 28 and facilitates EC barrier dysfunction through protein kinase C␣/RhoA-mediated cytoskeletal signaling, 29 indicating its proatherogenic role in ECs. Furthermore, treatment of cultured ECs with LPC appears to induce Ca 2ϩ -dependent calpain activation and ERK activation. 30, 31 It is noteworthy that ERK activation is capable of sensitizing m-calpain to Ca 2ϩ . 32 Because such biochemical sensitization is functional in living cells, m-calpain can be activated intracellularly.
Although LPC is abundantly present in plasma, local production of LPC from LDL by sPLA 2 enzymes in the arterial wall has been considered to play an important role in the process of atherosclerosis, 33, 34 and an sPLA 2 inhibitor is now under clinical trial for the treatment of atherosclerosis. 35 Indeed, LDL treated with sPLA 2 s contained large amounts of LPC ( Figure I . m-Calpain (Cal) directly cleaves VE-cadherin (VE-cad) at the juxtamembrane region. A, VE-cadherin is preferentially cleaved by m-calpain. Tagged VE-cadherin was collected by immunoprecipitation and was incubated withor m-calpain at indicated doses for 40 minutes. The graph represents the ratio of 90-kDa to intact VE-cadherin. nϭ3. *PϽ0.05 vs untreated by 1-way ANOVA followed by the Dunnett test. B, VE-cadherin lacking AA691-695 is resistant to m-calpain-induced proteolysis. Immunoprecipitated wild-type VE-cadherin (wild) or mutants (671⌬5, 681⌬5, and 691⌬5) were incubated with recombinant 16.5 g/mL m-calpain for 20 minutes. The graph represents the ratio of 90-kDa to intact VE-cadherin. nϭ3. *PϽ0.05 vs wild-type by 1-way ANOVA followed by the Dunnett test. C, The 691⌬5 mutant is resistant to lysophosphatidylcholine (LPC)-induced adherence junctions (AJ) breakdown. Top images show the time series of LPC (10 mol/L)-induced dynamics of green fluorescent protein (GFP) fusion VE-cadherin in wild-type cells and mutants. Line graph represents temporal changes in transendothelial electric resistance (TEER) in LPC-stimulated wild-type or mutant endothelial cell (EC) monolayer. The bar graph indicates relative changes in TEER at 60 minutes after the addition of 10 mol/L LPC vs baseline. nϭ4. *PϽ0.05 vs wild-type by 1-way ANOVA followed by the Dunnett test. D, The 691⌬5 mutant is resistant to LPC-induced EC hyperpermeability. The cells were subjected to 10 mol/L LPC for 1 hour. nϭ5. *PϽ0.05 by 2-way ANOVA and the Bonferroni test. E, Schematic depiction of molecular mechanisms underlying m-calpain-mediated progression of atherosclerosis. Step 1: in the early phase of atherosclerosis, m-calpain is induced in vascular ECs by the action of LPC derived from modified low-density lipoprotein (LDL). Step 2: upregulated m-calpain directly cleaves VE-cadherin at its juxtamembrane regions. Step 3: VE-cadherin cleavage leads to disorganization of AJs and subsequent infiltration of immune cells or plasma constituents into the intimal space.
